{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"2"}]}],"title":"AST GR1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"}]}],"title":"AST GR2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}],"title":"AST GR3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}],"title":"AST GR4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"2"}]}],"title":"High ALT GR1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"}]}],"title":"High ALT GR2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"}]}],"title":"High ALT GR3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}],"title":"High ALT GR4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"}]}],"title":"Total Bilirubin GR1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"}]}],"title":"Total Bilirubin GR2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}],"title":"Total Bilirubin GR3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}],"title":"Total Bilirubin GR4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}],"title":"High Serum Creatinine GR1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"}]}],"title":"High Serum Creatinine GR2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}],"title":"High Serum Creatinine GR3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}],"title":"High Serum Creatinine GR4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"6"}],"units":"Participants"}],"description":"GR1=Mild; GR2=Moderate; GR3=Severe; GR4=Life-threatening or disabling. Normal ranges provided by local laboratory and may also vary from site to site. AST and ALT: GR1=\\>ULN-2.5\\*ULN; GR2=\\>2.5-5.0\\*ULN; GR3=\\>5.0-20.0\\*ULN; GR4:\\>20.0\\*ULN. Total bilirubin:GR1=\\>ULN-1.5\\*ULN, GR2=\\>1.5-3.0\\*ULN, GR3=\\>3-10\\*ULN, GR4=\\>10\\*ULN. Creatinine: GR1=\\>ULN-1.5\\*ULN, GR2=\\>1.5-3.0\\*ULN, GR3=\\>3.0-6.0\\*ULN, GR4=\\>6.0\\*ULN.","groups":[{"description":"Participants with imatinib-resistant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP). Dasatinib 60 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG000","title":"Stratum 1 Ph+ CP-CML (Dasatinib 60 mg/m^2)"},{"description":"Participants with imatinib-resistant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP). Dasatinib 80 mg/m\\^2, as long as clinical benefit was maintained.","id":"OG001","title":"Stratum 1 Ph+ CP-CML (Dasatinib 80 mg/m^2)"},{"description":"Participants with imatinib-resistant or imatinib-intolerant Ph+ CML in accelerated phase (AP), or in myeloid blast phase (MBP), or in lymphoid blast phase (LBP); or relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL) after imatinib use; or second or subsequent relapse of Ph+ acute myeloid leukemia (AML). Dasatinib 60 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG002","title":"Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2)"},{"description":"Participants with imatinib-resistant or imatinib-intolerant Ph+ CML in accelerated phase (AP), or in myeloid blast phase (MBP), or in lymphoid blast phase (LBP); or relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL) after imatinib use; or second or subsequent relapse of Ph+ acute myeloid leukemia (AML). Dasatinib 80 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG003","title":"Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2)"},{"description":"Participants with second or subsequent relapse of Ph- ALL or Ph- AML. Dasatinib 60 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG004","title":"Stratum 4 Ph- ALL/AML (Dasatinib 60 mg/m^2)"},{"description":"Participants with second or subsequent relapse of Ph- ALL or Ph- AML. Dasatinib 80 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG005","title":"Stratum 4 Ph- ALL/AML (Dasatinib 80 mg/m^2)"},{"description":"Participants with second or subsequent relapse of Ph- ALL or Ph- AML. Dasatinib 100 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG006","title":"Stratum 4 Ph- ALL/AML (Dasatinib 100 mg/m^2)"},{"description":"Participants with second or subsequent relapse of Ph- ALL or Ph- AML. Dasatinib 120 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG007","title":"Stratum 4 Ph- ALL/AML (Dasatinib 120 mg/m^2)"}],"paramType":"NUMBER","populationDescription":"All treated participants: Participants who received at least one dose of study therapy.","reportingStatus":"POSTED","timeFrame":"Days 22 and 43, then every 12 weeks, then every 24 weeks after 24 months of treatment, EOT (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63]; Stratum 2/3=3.02 [Range: 0.53-37.72]; Stratum 4=1.14 [Range: 0.03-3.38])","title":"Number of Participants With Serum Chemistry Abnormalities (Liver and Renal Function) by NCI CTCAE Version 3.0","type":"SECONDARY","unitOfMeasure":"participants"}